{"disease":{"id":"neurogenic-detrusor-overactivity","name":"Neurogenic Detrusor Overactivity","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"onabotulinumtoxina","indication_name":"Neurogenic Detrusor Overactivity","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Botox","generic_name":"ONABOTULINUMTOXINA","company_name":"Allergan","drug_phase":"marketed","molecular_target":"SNAP-25","drug_class":"Acetylcholine Release Inhibitor [EPC]","quality_score":60,"revenue":"5300","mechanism":"BOTOX blocks neuromuscular transmission by inhibiting acetylcholine release through cleavage of SNAP-25."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02751931","title":"Open-label Phase 3 Study With Mirabegron in Children From 3 to Less Than 18 Years of Age With Neurogenic Detrusor Overactivity","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":91,"lead_sponsor_name":"Astellas Pharma Europe B.V.","has_results":true},{"nct_id":"NCT06059066","title":"Optimization of OnabotulinumtoxinA (BTX-A) Injection for the Treatment of Neurogenic Lower Urinary Tract Dysfunction","phase":"NA","overall_status":"COMPLETED","enrollment_count":78,"lead_sponsor_name":"The Methodist Hospital Research Institute","has_results":true},{"nct_id":"NCT01565694","title":"A Study to Assess the Long Term Effect, Safety and Metabolism of a Solifenacin Liquid Suspension in Participants 5 to 18 Years of Age With Neurogenic Detrusor Overactivity","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":76,"lead_sponsor_name":"Astellas Pharma Europe B.V.","has_results":true},{"nct_id":"NCT03482037","title":"Effects of Rec 0/0438 in Patients With Neurogenic Detrusor Overactivity Due to Spinal Cord Injury","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":42,"lead_sponsor_name":"RECORDATI GROUP","has_results":false},{"nct_id":"NCT04452838","title":"Study To Assess The Bioequivalence Under Fed And Fasted Conditions Of The Fesoterodine Beads-In-Capsule SR4 And SR7 Formulations And To Estimate The Bioavailability of SR7 Beads Sprinkled On Apple Sauce Relative To The Beads-In-Capsule SR7 Formulation Administer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT00712322","title":"A Two-week Open-label Pharmacodynamic and Pharmacokinetic Study of Multiple Doses of a Darifenacin Liquid Oral Suspension in Children (2 - 15 Years) With Neurogenic Detrusor Overactivity","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":35,"lead_sponsor_name":"Warner Chilcott","has_results":true},{"nct_id":"NCT04543552","title":"A Comparative Analysis of Portable Bladder Scanner to Determine Age/ Volume Specific Accuracy in 0-6 Years of Children","phase":"","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT02211846","title":"A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"Astellas Pharma Inc","has_results":false},{"nct_id":"NCT01981954","title":"A Clinical Study to Investigate How Solifenacin Fluid is Taken up, How Long it Stays in the Body and How Effective and Safe it is in Treating Children Aged From 6 Months to Less Than 5 Years With Symptoms of Neurogenic Detrusor Overactivity (NDO)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":23,"lead_sponsor_name":"Astellas Pharma Europe B.V.","has_results":true},{"nct_id":"NCT06515223","title":"Improving Pelvic Rehabilitation Using Epidural Stimulation After Spinal Cord Injury","phase":"NA","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"University College, London","has_results":false},{"nct_id":"NCT04478357","title":"BIOEQUIVALENCE STUDY IN HEALTHY PARTICIPANTS COMPARING 4 MG AND 8 MG FESOTERODINE EXTENDED-RELEASE TABLETS (TOVIAZ™), MANUFACTURED AT ZWICKAU VERSUS FREIBURG","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT01539707","title":"Single Dose Study to Measure Blood Levels and Safety of a Drug for Children With Overactive Bladder","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":14,"lead_sponsor_name":"Astellas Pharma Inc","has_results":false},{"nct_id":"NCT05502614","title":"Dorsal Genital Nerve Stimulation for Bladder Management After SCI","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":10,"lead_sponsor_name":"University College, London","has_results":false},{"nct_id":"NCT02526979","title":"A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron Oral Suspension in Pediatric Subjects From 3 to Less Than 12 Years of Age With Neurogenic Detrusor Overactivity (NDO) or Overactive Bladder (OAB)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":9,"lead_sponsor_name":"Astellas Pharma Europe B.V.","has_results":false},{"nct_id":"NCT03168828","title":"Safety and Tolerability of TAR-302-5018 in Subjects With Neurogenic Detrusor Overactivity Resulting From Spinal Cord Injury","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":7,"lead_sponsor_name":"Taris Biomedical LLC","has_results":false},{"nct_id":"NCT05621616","title":"A Study to Learn How Effective and Safe the Drug 'Mirabegron' is and How Long it Stays in the Body of Children Aged 6 Months to Less Than 3 Years of Age With Neurogenic Detrusor Overactivity","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":7,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":false}],"total":16},"guidelines":[],"source":"Drug Landscape verified database"}